Emily Leproust
American scientist and entrepreneur
Emily Leproust is an American scientist and entrepreneur. She is the CEO and co-founder of Twist Bioscience, a public company working on DNA synthesis.2
From Wikipedia’s article on Emily Leproust (this version), CC BY-SA 4.0.
About
The company harnesses synthetic biology, providing tools to manufacture insulin from yeast, to tackle malaria, produce spider silk at scale or store information on DNA. She was awarded the BIO Rosalind Franklin Award in 2020.
From Wikipedia’s article on Emily Leproust, shared under CC BY-SA 4.0.2
Companies
- GeneDx Holdings Corp.Board member Sep 1, 2020 to now13
- Twist BioscienceBoard member Oct 30, 2018 to now14
- Twist BioscienceChief executive officer Oct 30, 2018 to now14
- Twist BioscienceFounder15
- Twist BiosciencePresident Oct 30, 2018 to Oct 4, 202214
Holdings
Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.
Shares held
- Twist Bioscience TWST613,699 shares16$86.3M at $140.69Sep 24, 2026
- GeneDx Holdings Corp. WGS24,852 shares17$1.6M at $66.17Jun 18, 2026
As of each latest filing. The line shows shares held over time.
Recent filings
- Sep 24, 2026Sold 83 shares at $184.60 of Twist Bioscience16
- Sep 24, 2026Sold 501 shares at $183.76 of Twist Bioscience16
- Sep 24, 2026Sold 16 shares at $182.50 of Twist Bioscience16
- Sep 24, 2026Sold 21 shares at $181.45 of Twist Bioscience16
- Sep 24, 2026Sold 515 shares at $180.39 of Twist Bioscience16
- Sep 24, 2026Sold 143 shares at $179.93 of Twist Bioscience16
- Sep 24, 2026Sold 330 shares at $178.67 of Twist Bioscience16
- Sep 24, 2026Sold 164 shares at $177.17 of Twist Bioscience16
- Sep 24, 2026Sold 945 shares at $176.39 of Twist Bioscience16
- Sep 24, 2026Sold 2,485 shares at $175.23 of Twist Bioscience16
- Sep 21, 2026Sold 1,687 shares at $165.49 of Twist Bioscience18
- Sep 17, 2026Sold 869 shares at $163.39 of Twist Bioscience19
- Sep 17, 2026Sold 2,565 shares at $162.31 of Twist Bioscience19
- Sep 17, 2026Sold 11,169 shares at $161.49 of Twist Bioscience19
- Sep 17, 2026Sold 14,493 shares at $160.44 of Twist Bioscience19
- Sep 17, 2026Sold 23,884 shares at $159.53 of Twist Bioscience19
- Sep 17, 2026Sold 232,173 shares at $158.09 of Twist Bioscience19
- Sep 17, 2026Sold 32,260 shares at $157.49 of Twist Bioscience19
- Sep 17, 2026Sold 9,097 shares at $156.47 of Twist Bioscience19
- Sep 17, 2026Sold 13,378 shares at $155.46 of Twist Bioscience19
- Sep 17, 2026Sold 4,175 shares at $154.17 of Twist Bioscience19
- Sep 17, 2026Sold 3,399 shares at $153.40 of Twist Bioscience19
- Sep 17, 2026Sold 6,644 shares at $152.21 of Twist Bioscience19
- Sep 17, 2026Sold 2,440 shares at $151.46 of Twist Bioscience19
- Sep 17, 2026Exercised options 75,439 shares at $8.82 of Twist Bioscience19
Early life and education
Leproust earned an M.Sc. in Industrial Chemistry from the Lyon School of Industrial Chemistry in 1995 and a PhD in Organic Chemistry & Nucleic Acids Chemistry from the University of Houston in 2001. She worked for the company Agilent where she was Director of Applications and Chemistry R&D—Genomics before starting the company Twist Bioscience.
Leproust participated in a March 2021 tabletop exercise at the Munich Security Conference simulating an outbreak of weaponized monkeypox.
From Wikipedia’s article on Emily Leproust (this version), CC BY-SA 4.0.
Career
Occupation: entrepreneur, scientist.8
- Date not recordedWorked at Agilent Technologies5 6
- Date not recordedFounded Twist Bioscience7
Legal issues and controversies
On February 6, 2020, Twist Bioscience agreed to pay $22.5 million in settlement with Agilent. "Agilent sued Twist in 2016, alleging that Twist CEO and cofounder Emily Leproust stole trade secrets when she left Agilent to launch the provider of custom DNA products and services."
A class action case alleging fraud against Leproust and her company is pending. "Plaintiffs allege that from December 13, 2019 through November 14, 2022, Twist and its senior management misrepresented that the company possessed innovative proprietary technology to produce synthetic DNA at a higher quality and lower cost than competitors, positioning Twist for significant future growth. Plaintiffs further allege that defendants engaged in accounting improprieties to conceal the scheme."
On November 15, 2022, Scorpion Capital issued an exhaustive, 236-page short-seller report alleging serious fraud at Leproust's company, Twist Bioscience. The company called the report "misleading" and "inaccurate".
From Wikipedia’s article on Emily Leproust (this version), CC BY-SA 4.0.
Awards
Links
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataEmily Leproust on Wikidata
- 2WikipediaEmily Leproust on Wikipedia
- 3
- 4Wikidataeducation, as reported
- 5
- 6
- 7
- 8
- 9
- 10Wikidataaward, as reported
- 11WikidataEmily Leproust: X, on Wikidata
- 12
- 13SEC EDGARGeneDx Holdings Corp., Board member
- 14SEC EDGARTwist Bioscience, Board member
- 15WikidataTwist Bioscience, Founder
- 16
- 17
- 18SEC EDGARForm 4 filed Sep 23, 2026
- 19SEC EDGARForm 4 filed Sep 21, 2026